Events

Oliver Wyman Webinar w/ Ivan Griffin

Join Ivan Griffin, BenevolentAI’s COO and Co-Founder, for a webinar on using AI and machine learning to transform drug discovery.

Artificial intelligence and machine learning are rapidly reshaping the healthcare landscape. By tapping into these analytic tools, pharma can develop better targeted care solutions. With 9 out of 10 candidate therapies failing somewhere between phase I trials and regulatory approval, new drug development—which can cost nearly $2.6 billion according to some estimates—is ripe for disruption. AI and machine learning has the potential to help the industry develop more effective drugs quicker and at a lower cost.

Dr Ivan Griffin, COO & Co-Founder of BenevolentAI, will share his views on the industry and how it could develop.

Link to event -->


Ivan Griffin

COO & Co-Founder, BenevolentAI

Ivan is COO and a Co-Founder of BenevolentAI. He has 10 years’ experience as a venture capitalist encompassing all aspects of technology commercialization; identification of opportunities, company formation, business development, private and public equity financings and trade sales. He also helped launch Genomics England Ltd, a Company created to deliver the 100,000 Genomes Project as launched by the Prime Minister in 2013. Ivan holds a D.Phil. in Cognitive Neuroscience from the University of Oxford where he also completed a year’s post-doctoral research.

More Posts

You Might Also Like

Video
Data & Digital Innovation for Climate & Health
Joanna Shields, CEO BenevolentAI, joined the Wellcome Trust Panel at the World Economic forum to discuss opportunities for data and digital innovation to impact positively climate and health.
Jan 26, 2023
News
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022